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Voiding Dysfunction
Effect of Obesity on Prostate-Specific Antigen, Prostate Volume, 
and International Prostate Symptom Score in Patients with Benign 
Prostatic Hyperplasia
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Purpose: We examined the correlation between body mass index (BMI) as a marker 
of obesity and prostate-specific antigen (PSA), prostate volume (PV), and International 
Prostate Symptom Score (IPSS) in patients with benign prostatic hyperplasia (BPH). 
Materials and Methods: From January 2008 to December 2008, we examined 258 pa-
tients diagnosed with BPH. Patients taking 5α-reductase inhibitors or those diagnosed 
with prostate cancer were excluded from this study. BPH was defined as PV≥25 ml 
and IPSS≥8. BMI (kg/m
2) was categorized into 4 groups as follows: BMI＜18.5 (under-
weight), BMI 18.5-23.0 (normal), BMI 23.0-27.5 (overweight), and BMI＞27.5 (obese). 
The relationships between PSA, PV, IPSS, and BMI were analyzed by correlation analy-
sis and one-way ANOVA.
Results: The mean age of the patients was 65.19±9.13 years and their mean BMI was 
23.7±4.4 kg/m
2. The mean PSA values of each BMI group were as follows: 3.42±1.53,
3.07±1.88, 2.74±1.75, and 2.60±1.44 ng/ml. The PSA value was lowest in the obese 
group. The correlation analysis showed a negative correlation between BMI and PSA 
(Pearson’s correlation coefficient=−0.142, p=0.023) and positive correlations between 
BMI and PV (Pearson’s correlation coefficient=0.32, p=0.001) and IPSS (Pearson’s cor-
relation coefficient=0.470, p=0.02). These correlations were also confirmed by one-way 
ANOVA. 
Conclusions: Patients with an elevated BMI tended to have lower PSA values, larger 
PVs, and a higher IPSS. We suggest that weight loss could be helpful for BPH symptom 
relief as well as for detection of coexisting prostate cancer in BPH patients. 
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a prevalent problem 
among older men, and its incidence is expected to increase 
as the human lifespan is prolonged. Symptoms of BPH, 
such as lower urinary tract symptoms (LUTS), have a neg-
ative impact on quality of life [1].
　Prostate-specific antigen (PSA) is the most important 
prostate cancer screening tool and the majority of prostate 
cancers are detected with biopsy after abnormal PSA 
results. The ability to accurately detect prostate cancer can 
be compromised by any factor that decreases PSA. Several 
studies have found that obese men have lower PSA values 
than do nonobese men [2-7]. Because of hemodilution by 
the large plasma volume in obese men, some investigators 
have hypothesized that the PSA value is underestimated 
in obesity [8]. 
　Multiple studies have reported that obese men have a 
larger prostate volume (PV) [9-13], and recently some stud-
ies have also revealed that a relationship exists between 
obesity and LUTS [9,11,14,15]. There have been few stud-
ies, however, concerning the effect of obesity on LUTS as Korean J Urol 2011;52:401-405
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Age (yr) BMI (kg/m
2) PSA (ng/ml) PV (ml) IPSS (Obstructive/Irritative)
50-59 (n=61) 23.71±5.36 2.45±1.49 41.27±19.34
18.32±6.07 
(10.14±2.19/5.51±2.04)
60-69 (n=114) 23.96±4.12 2.87±1.83 48.37±26.92
19.59±5.76 
(12.51±2.63/7.02±3.29)
70-79 (n=83) 23.24±3.92 3.27±2.06 55.61±23.42
21.66±6.63 
(14.05±3.25/9.53±2.86)
PSA: prostate-specific antigen, BMI: body mass index, PV: prostate volume, IPSS: International Prostate Symptom Score
TABLE 1. Mean BMI, PSA and IPSS including subscores according to age group (n=258)
Mean±SD
p-value
Underweight (n=40) Normal weight (n=72) Overweight (n=85) Obese (n=61)
Age (yr)   62.10±11.07 68.26±9.35 66.35±7.19 63.16±8.82 0.753
PSA (ng/ml)   3.42±1.53   3.07±1.88   2.74±1.75   2.60±1.44 0.023
a
PV (ml)   35.40±12.82   46.78±24.34   49.53±27.14   59.95±26.27 0.007
a
IPSS 15.13±3.96 17.90±5.98 20.19±6.77 25.07±5.22 0.023
a
   Subscore of obstructive symptom   9.87±2.45 11.04±3.88 12.74±4.52 15.39±3.76 0.043
a
   Subscore of irritative symptom   5.26±1.68   6.86±1.96   7.45±3.29    9.68±2.84 0.039
a
BMI: body mass index, PSA: prostate-specific antigen, PV: prostate volume, IPSS: International Prostate Symptom Score, 
a: p＜0.05
TABLE 2. Comparison of the study subjects by BMI
well as BPH parameters in Korean men, especially sympto-
matic BPH patients. Furthermore, we think it might be 
meaningful to investigate this correlation in a single insti-
tution. Therefore, we examined the correlation between 
body mass index (BMI) as a marker of obesity and PSA, PV, 
and International Prostate Symptom Score (IPSS) in symp-
tomatic BPH patients.
MATERIALS AND METHODS
From January 2008 to December 2008, we retrospectively 
investigated 258 patients diagnosed with BPH in our insti-
tution. All patients underwent detailed clinical evaluations 
with the IPSS questionnaire and blood tests including PSA 
values. Transrectal ultrasound (TRUS) of the prostate was 
also performed. Anthropometric measurements including 
height and weight were performed. BMI was calculated as 
weight in kilograms divided by the square of height in me-
ters (kg/m
2). IPSS was used as the objective scale for degree 
of LUTS.
　BPH was defined as a PV≥25 ml and IPSS≥8, which are 
commonly used as clinical BPH criteria [16]. BMI (kg/m
2) 
groups were categorized according to the WHO BMI cri-
teria for Asians as follows: underweight (BMI ＜18.5), nor-
mal weight (BMI 18.5-23.0), overweight (BMI 23.0-27.5), 
and obese (BMI≥27.5) [17].
　The exclusion criteria of this study were the use of medi-
cations affecting prostate growth, such as 5-α-reductase in-
hibitors and antiandrogens; the presence of neurogenic 
bladder dysfunction; confirmed prostate cancer by needle 
biopsy of the prostate; acute or chronic urinary retention 
status; a history of recurrent urinary tract infection or blad-
der stones; acute or chronic prostatitis within the previous 
3 months; and a previous surgical procedure related to 
BPH. 
　Statistical analyses were performed by using the SPSS 
ver. 17.0 (SPSS Inc., Chicago, IL, USA) PSA values were 
natural-log-transformed to improve normality and to con-
trol for age when presenting the results because of the 
known association between PSA and age [18]. Thus, mean 
values of PSA are presented as age-adjusted (geometric) 
means in the figure but are referenced as mean PSA in the 
text, including tables, to simplify matters. One-way analy-
sis of variance (ANOVA) was used to determine the stat-
istical significance of the differences in age, PSA, PV, and 
IPSS among the groups according to BMI. Univariate anal-
ysis by Pearson’s correlation coefficient was used to test the 
linearity of the relationships between PSA, PV, IPSS, and 
BMI. A p-value of ＜0.05 was considered statistically signi-
ficant.
RESULTS
1. Subjects characteristics 
The mean age of the patients was 65.19±9.13 years and 
their mean BMI was 23.7±4.4 kg/m
2. Of the subjects,11 
(4.3%) were diagnosed with hypertension and 19 (7.4%) 
with diabetes mellitus. All of the patients had been using 
medication and had well-controlled blood pressure or plas-
ma glucose levels. No subjects had diagnosed metabolic 
syndrome. 
　The BMI distribution of the 258 subjects was as follows: 
40, 72, 85, and 61 in the underweight (15.5%), normal weight 
(27.9%), overweight (32.9%), and obese (23.7%) groups, Korean J Urol 2011;52:401-405
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respectively. Mean PSA, BMI, PV, and IPSS including sub-
scores according to each age group are shown in Table 1. 
Shown in Table 2 are the comparsions of the study subjects 
in each BMI group.
2. Prostate-specific antigen
The mean PSA value was 3.42±1.53, 3.07±1.88, 2.74±1.75, 
and 2.60±1.44 ng/ml in each BMI group. The PSA value was 
lowest in the obese group. There were significant differences 
in PSA values among the BMI groups (p=0.023) (Table 2).
3. Prostate volume
The mean PV was 35.40±12.82, 46.78±24.34, 49.53±27.14, 
and 59.95±26.27 ml in each BMI group. PV was largest in 
the obese group. There were significant differences in PV 
among the BMI groups (p=0.007) (Table 2).
4. International Prostate Symptom Score
The mean IPSS was 15.13±3.96, 17.90±5.98, 20.19±6.77, 
and 25.07±5.22 in each BMI group. The IPSS and subscores 
for obstructive and irritative symptoms were highest in the 
obese group. There were significant differences in IPSS 
among the BMI groups (p＜0.05) (Table 2). 
5. Associations between PSA, PV, IPSS and BMI
We examined the relationships between PSA, PV, IPSS, 
and BMI. In the univariate analysis by Pearson’s correlation 
coefficient, BMI correlated negatively with PSA (p=0.023) 
and positively with PV (p=0.001) and IPSS (p=0.02). The 
correlation coefficients of PSA, PV, and IPSS were −0.142, 
0.320, and 0.470, respectively (Fig. 1).
DISCUSSION
Over the past decades, many different groups have inves-
tigated the influence of obesity on the developmentof BPH 
with conflicting results [19-23]. Freedland et al examined 
the association between BMI and PSA among men who un-
derwent radical prostatectomy for prostate cancer. They 
found no association between BMI and PSA [24]. However, 
Bañez et al examined the association between obesity-re-
lated plasma hemodilution and PSA concentration among 
men who underwent radical prostatectomy for prostate 
adenocarcinoma. They suggested that the PSA value was 
underestimated in obesity and that lower PSA values were 
largely due to hemodilution by the large plasma volume in 
obese men [8]. Sohn et al investigated the association be-
tween BMI and PSA among 26,912 Korean men who visited 
health promotion centers. They noted that BMI was in-
versely correlated with PSA [25]. In this study, the mean 
PSA value was lowest in the obese group. In the univariate 
analysis by Pearson’s correlation coefficient, BMI corre-
FIG. 1. Univariate analysis by Pearson’s correlation coefficient 
between BMI and PSA, PV, and IPSS. (A) Correlation between
BMI and PSA (Pearson’s correlation coefficient= −0.142, p= 
0.023), (B) Correlation between BMI and PV (Pearson’s correla-
tion coefficient=0.320, p=0.001), (C) Correlation between BMI 
and IPSS (Pearson’s correlation coefficient=0.470, p=0.02). 
BMI: body mass index, PSA: prostate-specific antigen, PV: pros-
tate volume, IPSS: International Prostate Symptom Score. Korean J Urol 2011;52:401-405
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lated negatively with PSA (p=0.023).
　In terms of correlation between PV and BMI, Kim et al 
investigated the relationship of PV with metabolic and an-
thropometric parameters. They reported that PV corre-
lated positively with weight and height, but there was no 
statistical correlation between PV and BMI in the multi-
variable linear regression analysis [26]. A recent study of 
465 men recruited through a health promotion center 
showed that PV was positively correlated with central obe-
sity, as represented by waist circumference, but not with 
overall obesity, as represented by BMI [27]. By contrast, 
a US study of men who had undergone radical prostatec-
tomy reported that BMI was positively associated with PV 
in those younger than 63 years [24]. In another study of men 
shown by biopsy to be without prostate cancer, BMI was 
directly associated with PV [28]. 
　Obesity may influence prostatic enlargement and may 
also worsen urinary obstructive symptoms by increasing 
activity of sympathetic nervous systems [29]. Kristal et al 
examined several modifiable lifestyle factors related to the 
development of symptomatic BPH in 5,600 men enrolled 
in the placebo arm of the Prostate Cancer Prevention Trial 
who were followed for 7 years [19]. They reported signi-
ficant increases in symptomatic BPH (IPSS＞14) with 
obesity. Therefore, they suggested that obesity in adult-
hood was associated with a higher prevalence of LUTS. 
Rohrmann et al investigated the association between obe-
sity and LUTS in the National Health and Nutrition 
Examination Survey (NHANES) III cohort [14]. They rec-
ognized that an increase in BMI after age 25 was positively 
associated with LUTS. 
　We examined patients who visited the department of 
urology and were diagnosed with BPH. The results of our 
study showed that the mean value of PV and IPSS increa-
sed with elevated BMI. In the correlation analysis, BMI 
correlated positively with PV (p=0.001) and IPSS (p=0.02). 
The correlation coefficients for PV and IPSS were 0.320 and 
0.470, respectively.
　Several recent studies concerning the relationships be-
tween BMI and BPH parameters have been reported, but 
these studies included healthy populations of men who vis-
ited a health promotion center. In the present study, we 
studied symptomatic BPH patients who visited the depart-
ment of urology for evaluation or treatment. It was an aim 
of our study to reveal the relationship between BMI and 
BPH parameters in symptomatic BPH patients. Therefore, 
we think that it might be meaningful to announce the re-
sults of this study to BPH patients.
CONCLUSIONS
Patients with a large BMI tended to have a lower PSA value, 
larger PV, and higher IPSS. We hypothesize that weight 
loss could help in the relief of LUTS in BPH patients. We 
also note that the PSA value was underestimated in obesity. 
To prevent delay in early diagnosis of coexisting prostate 
cancer in obese patients, a study of prostate cancer screen-
ing in coordination with BMI is warranted. 
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